Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea. Research shows that it considerably improves the level of AHI in patients with ...

The ΔCO, which is the gap between the presleep and postsleep venous CO levels, was positively correlated with AHI and with hypoxia ... related to hypoxia during sleep in OSA patients.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

ILI was associated with an improvement of obstructive sleep apnea, determined by a mean AHI decrease of 9.7 events per hour compared with that in the DSE patient group. Study participants with a ...

More information: Vanessa Cavalcante-Silva et al, Homocysteine as a predictor of apnea–hypopnea index in obstructive sleep ...

Obstructive Sleep Apnea (OSA) is a common sleep disorder in children characterized by repeated interruptions in breathing during sleep due to the obstruction of the upper airway. This condition ...

The trials' main goal was improvement on a metric known as the apnea-hypopnea index, or AHI, the number of breathing disruptions during an hour of sleep. In both studies, the mean AHI to start was ...

The trials assessed participants using the apnea-hypopnea index (AHI), which measures the frequency of breathing interruptions during sleep. In one trial where participants did not use CPAP, Zepbound ...

The main measure of effectiveness was the change in the apnea hypopnea index (AHI), which tracks how often a person stops or has shallow breaths during sleep. After 52 weeks of treatment ...